Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938917 | PMC |
| http://dx.doi.org/10.1016/j.jdcr.2019.11.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Radiological and Pathological Analysis of Pembrolizumab-Associated Lung Lesions: Diagnostic Challenges and Management.
Am J Case Rep
January 2025
Department of Pulmonary and Critical Care Medicine, Faculty and Graduate School of Medicine, Mie University, Tsu, Mie, Japan.
BACKGROUND Pembrolizumab, a programmed cell-death protein-1 (PD-1)-targeting antibody, extends survival in cancer patients but may cause lung injury as a side effect. This immunotherapy enhances the immune system's ability to recognize and eliminate cancer cells. However, its immunomodulatory action can sometimes lead to immune-related adverse events, including lung injury.
View Article and Find Full Text PDFMyositis associated with pembrolizumab presenting with myastheniform symptoms: two case reports.
Anticancer Drugs
February 2025
Department of Neurology, Bezmialem Vakif University, Medical Faculty, Istanbul, Turkey.
Immune checkpoint inhibitors (ICIs), such as pembrolizumab, have revolutionized cancer treatment by enhancing the immune system's response to malignancies. However, these therapies are associated with immune-related adverse events (irAEs), including neuromuscular complications such as myasthenia gravis, myositis, and myocarditis. We describe two male patients, aged 67 and 68, with small cell and non-small cell lung cancers, who developed progressive neuromuscular symptoms, including ptosis, diplopia, and generalized weakness, after receiving pembrolizumab.
View Article and Find Full Text PDFThe role of CD73 in predicting the response to immunotherapy in head and neck cancer patients.
Pathol Res Pract
August 2024
Department of Medico-Surgical Sciences and Biotechnology, Polo Pontino, Sapienza University, Roma 00185, Italy. Electronic address:
Article Synopsis
- Immunotherapy is important for treating recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC), but few patients experience long-term benefits due to an immunosuppressive tumor environment.
- This study investigated how the expression of the protein CD73 by both cancer and immune cells influences the effectiveness of anti-PD-1 immunotherapy in patients.
- Results showed that high CD73 levels on cancer cells are linked to early disease progression, suggesting that evaluating CD73 could help identify patients who are likely to resist treatment.
Delayed Pembrolizumab-Associated Sarcoidosis.
Am J Ther
July 2024
Division of Hematology Oncology, Department of Internal Medicine, Body School of Medicine/East Carolina University, Greenville, NC.
Autoimmune Encephalitis following Checkpoint Inhibitor Therapy in a Patient with Metastatic Melanoma in Complete Remission.
Medicina (Kaunas)
April 2024
Internal Medicine and Oncology, Casa di Cura Piacenza, 29121 Piacenza, Italy.
The use of immune checkpoint inhibitors (ICIs) in cancer is increasing. Their side effects are mainly due to the triggering of autoimmunity, which are mild or moderate and include skin rash, colitis, hepatitis, endocrine disorders, myositis, interstitial lung disorder, etc., in most cases during the course of therapy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!